
Three natural food dyes approved by FDA as RFK Jr. says industry is 'stepping up'
Galdieria extract blue, butterfly pea flower extract and calcium phosphate can all be used now by any manufacturer for color-approved items.
"I'm pleased to report that 'promises made' have been 'promises kept,'" FDA Commissioner Martin Makary said in a news release.
Last month, the U.S. Department of Health and Human Services (HHS) and the FDA announced a ban on petroleum-based synthetic dyes within the nation's food supply, citing health concerns.
"FDA staff have been moving quickly to expedite the publication of these decisions, underscoring our serious intent to transition away from petroleum-based dyes in the food supply and provide new colors from natural sources," Makary also said.
Galdieria extract blue is a blue color derived from the unicellular red algae Galdieria sulphuraria.
It is approved for nonalcoholic beverages and beverage bases, breakfast cereal coatings, candies, frozen desserts, frostings and other sweet selections, according to the news release.
Butterfly pea flower extract, derived from water extraction of the dried flower petals of the butterfly pea plant, can achieve colors of blue, green and purple.
The dye is already approved for various drinks but has been expanded to cereals, crackers, candies and different snacks.
Calcium phosphate is a white color. It can be used now in chicken products and candies.
In a Saturday appearance on "Fox & Friends Weekend," HHS Secretary Robert F. Kennedy Jr. detailed the announcement.
He said the food industry "has really stepped up" and has been working together with federal agencies like the FDA.
"The industry is coming to the table. They are talking to us. They are taking this seriously," he added.
Vani Hari, Truvani founder and "Food Babe," told Fox News Digital on Monday that it's unprecedented to see the FDA moving so swiftly.
"After this change, the industry will have no excuses not to convert their products to more natural sources," said Hari.
"The industry will have no excuses not to convert their products to more natural sources."
"Petroleum-based dyes are linked to a litany of health issues and it's time American food companies serve us the same safer ingredients they already use in other countries."
Certified nutritionist and Realfoodology founder Courtney Swan told Fox News Digital, "We should have been using plant extracts all along."
She added, "They exist in nature and don't have risks like the synthetic lab-made ones we've been using."
Tyson Foods recently announced it intends to get rid of petroleum-based synthetic dyes from its products by the end of May, Fox News Digital reported.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
United Therapeutics Corporation (UTHR) Launches First UKidney Human Trial
We recently compiled a list of United Therapeutics Corporation stands sixth on our list and has launched the first UKidney human trial. United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company focused on treating rare, life-threatening diseases such as pulmonary arterial hypertension (PAH) and advancing technologies to address the shortage of transplantable organs. As the first major biotech to become a Public Benefit Corporation, it combines innovation with social impact, especially in organ transplantation. In 2025, the company launched the first human clinical trial of UKidney, a gene-edited pig kidney, in patients with end-stage renal disease (ESRD). The FDA cleared the IND in February, and the first transplant is expected by mid-year. The UKidney features ten genetic modifications to improve human compatibility. The initial trial includes six patients, with plans to expand to 50. United Therapeutics Corporation (NASDAQ:UTHR), often cited among the most undervalued stocks in the biotech industry, is investing $100 million in expanding its Silver Spring, Maryland, organ production campus. This facility will drive large-scale manufacturing of bioengineered organs, leveraging work by its subsidiary, Revivicor, which has already achieved successful pig-to-human organ transplants. In parallel, the business continues advancing therapies for PAH and pulmonary hypertension. It completed enrollment in its TETON-2 trial (inhaled treprostinil for idiopathic pulmonary fibrosis) with results expected later in 2025, and is progressing with other investigational drugs like rilaprag. A biotechnologist in a lab coat discussing a therapeutic antibody with a colleague. By pioneering xenotransplantation and expanding infrastructure, United Therapeutics Corporation (NASDAQ:UTHR) aims to revolutionize organ transplantation and significantly reduce the gap between organ supply and demand. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
36 minutes ago
- Yahoo
California doctor sued for ‘wrongful death' after shipping abortion drugs interstate in legal first
A Texas man is suing a doctor in California he claims mailed his girlfriend pills to end her pregnancy - in what may be a legal first - and a test of new state abortion laws. Jerry Rodriguez filed a wrongful death lawsuit against Remy Coeytaux, after the doctor sent the abortion-inducing drugs across state lines in order to 'murder his unborn son,' Rodriguez claimed. It appears to be the first time an interstate lawsuit for wrongful death over an abortion has been filed, according to The Washington Post. In Texas, a person who assists a pregnant woman in obtaining a self-managed abortion commits the crime of murder and can be sued for wrongful death, the lawsuit, filed in Texas federal court and obtained by The Independent, states. The woman herself cannot be prosecuted. The suit adds it is also a state jail felony for anyone other than a Texas-licensed physician to provide an abortion-inducing drug for the purpose of inducing an abortion. 'In violation of these and many other laws, defendant Remy Coeytaux mailed abortion-inducing drugs into Texas that were used to murder Jerry Rodriguez's unborn child,' the complaint reads. Rodriguez is suing Coeytaux for $75,000 over what he claims is wrongful death. He's also seeking an injunction to stop the doctor from distributing abortion-inducing drugs in violation of state or federal law. The injunction, the suit states, is being sought 'on behalf of a class of all current and future fathers of unborn children in the United States.' But such state legislation clashes with that of California, which retains a so-called 'Shield Law' to protect medical professionals such as Coeytaux. The law provides that 'California will not deliver a person accused or charged with committing a crime related to abortion/gender-affirming care over to law enforcement officials.' This includes situations where a California-licensed pharmacist dispenses an abortion-inducing drug mifepristone to a patient in a state with abortion-restrictive laws. According to Rodriguez's suit, he began dating his girlfriend in June 2024, while she was separated from her husband, but not yet divorced. The Independent has chosen not to name the woman, due to privacy reasons and because she is not a defendant in the lawsuit. The suit alleges that the woman's husband, Adam Garza, twice ordered the abortion medication from Coeytaux after she became pregnant by Rodriguez 'with the intent of using them to murder Mr. Rodriguez's unborn child,' and 'pressured her' to take the pills. A Venmo receipt confirming Garza's purchase of the drugs from Coeytaux was included in the lawsuit, with a reference of ''Aed axes' – allegedly a homonym for 'Aid Access,' an organization that ships abortion-inducing drugs into jurisdictions where abortion is not legal. 'Defendant Coeytaux caused the death of Mr. Rodriguez's unborn child through his wrongful acts,' the lawsuit states. 'Although [the woman] cannot be charged with murder for her role in killing her unborn child, her immunity does not shield Coeytaux from liability for aiding or abetting or directly participating in the murder.' 'Mr. Rodriguez seeks this injunction on behalf of a class of all current and future fathers of unborn children in the United States.' The Independent has reached out to Dr Remy Coeytaux for comment on the lawsuit.
Yahoo
38 minutes ago
- Yahoo
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment
We recently compiled a list of Vertex Pharmaceuticals Incorporated stands second on our list and has recently launched the first non opioid acute pain treatment. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a global biotech firm based in Boston, is known for developing innovative treatments for serious diseases like cystic fibrosis, sickle cell disease, and beta thalassemia. The company is recognized for its strong pipeline targeting unmet medical needs. In July 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) launched JOURNAVX (suzetrigine), a first-in-class, non-opioid treatment for moderate-to-severe acute pain. JOURNAVX, an oral NaV1.8 pain signal inhibitor, was named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc. It represents the first new class of pain medicine in decades and offers a safer alternative to opioids by directly targeting pain pathways without addiction risks. This launch marks a major advancement in pain management, aligning with public health efforts to reduce opioid use. JOURNAVX is especially relevant for acute pain scenarios such as post-surgical recovery and injury care. A closeup of pills in a pharmacy, representing the high quality medications of the company. Beyond acute pain, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) continues to expand its reach. Its next-gen cystic fibrosis therapy, ALYFTREK, received approval from the European Commission in July 2025, strengthening its global leadership in this area. The company is also advancing gene-editing therapies like CASGEVY for sickle cell and beta thalassemia, and is developing treatments for kidney disease, type 1 diabetes, and rare genetic disorders. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio